Win-Win Fine Chemical Expert

Hehuang Pharmaceuticals' Furoquitinib 'Approved for Market by FDA

On November 9th, Hehuang Pharmaceutical announced FRUZAQLA ? Furuintinib has been approved by the FDA for marketing, becoming the first and only highly selective inhibitor for all three types of VEGF receptor kinases approved for the treatment of metastatic colorectal cancer in the United States, regardless of the patient's biomarker status.

Read More...

CPHI World Wide2023

October 24-26, 2023, the world's largest pharmaceutical industry professional exhibition CPhI Worldwide will be held in Barcelona, Spain, the exhibition has been the world's pharmaceutical raw material industry practitioners active participation and widely recognized, become the world's pharmaceutical raw material industry practitioners annual gathering.

Read More...

Dazhe Pharmaceutical JAK1 inhibitor "Gulisidinib" domestic newspaper listing

On September 14, CDE's official website showed that Dazhe Pharmaceutical's high -selective JAK1 inhibitor Goriqitini new drug listing application has been accepted for the treatment of recurrence and refractory perimeter T cell lymphoma (R/R PTCL) Essence According to Dazhe's press release, this is the source innovative drug reported by the company's 2nd. Gulifitinib is the world's first high -selective JAK1 inhibitor in the world of T -cell lymphoma and so far in the NDA declaration stage. It has conducted key clinical trials in China, the United States, South Korea, and Australia.

Read More...

The first domestic weight loss magic medicine Licolatic peptide was approved to be listed on the market

The GLP-1 "weight loss magic medicine" of the fire was finally approved in China. On July 4th, East China Pharmaceutical Co., Ltd. (East China Pharmaceutical, 000963) issued an announcement saying that Hangzhou China and the United States East China Pharmaceutical Co., Ltd. ("China -US East China") received the National Drug Administration (NMPA) for approval The "Pharmaceutical Registration Certificate" issued by East China, China, and the United States, is approved by the listing license application of obesity or overweight indication certificates declared by China and the United States. Leralugin peptide is a human cordyl glucose-like peptide-1 (GLP-1) receptor agonist. It has 97%sequence homologous with human GLP-1 and is approved to improve adult type 2 diabetes (T2DM ) Blood glucose control and treatment of patients with obesity or overweight.

Read More...

CPHI & PMEC China 2023

CPHI & PMEC China 2023 was held at the SNIEC,Shanghai,China from June 19th to 21st. This exhibition attracted many exhibitors from all over the world, covering many raw materials, intermediates, medical devices and other multiple field. Win-Win Chemical and company employees participated in the exhibition perfectly, met professionals in industries from all over the world, and conducted in -depth exchanges with new and old customers to discuss cooperation. We are looking forward to meet you at CPHI next year!

Read More...

CPHI & PMEC China 2023

Our company will attend “CPhI China” in Shanghai, from Jun 19th to 21th, 2023. We welcome you to visit and discover our latest services and capabilities.To make an appointment, please contact email sales@win-winchemical.com

Read More...